Kodali Sreenath, Rajendran Tara, Richard Ivan N, Boyapati Lakshmi, Wong Edward C C, Avezbakiyev Boris
Division of Hematology/Oncology, Brookdale University Hospital Medical Center, 1Brookdale Plaza, Brooklyn, NY 11212, USA.
Quest Diagnostics Nichols Institute, Chantilly, VA, USA.
J Hematol. 2019 Dec;8(4):155-159. doi: 10.14740/jh538. Epub 2019 Dec 25.
Painless bleeding in a patient presenting from the community with elevated coagulation studies rarely makes the physicians suspect superwarfarin or rodenticide poisoning. Although a significant number of superwarfarin exposure cases are diagnosed every year, we believe there appears to be delay in diagnosis and confusion in determining what is the ideal way to treat and monitor these patients during the management. This is the first thorough literature review of all the reported cases of superwarfarin poisoning which also studied the clinical presentation, management and follow-up patterns. We present a 70-year-old man who presented to the emergency room with epistaxis, melena, cola-colored urine with elevated prothrombin time (PT), activated partial thromboplastin time (aPTT) and international normalized ratio (INR). Mixing studies showed complete correction of coagulopathy indicative of factor deficiency. Additional history revealed that the patient had arguments with family member at home and made us suspect superwarfarin exposure. Qualitative brodifacoum testing was positive and was managed with fresh frozen plasma and high doses of vitamin K1 (phytomenadione) with serial monitoring of INR and clinical symptoms. Superwarfarin poisoning should be considered in the differential diagnosis of a patient who presents with above clinical and laboratory profile especially in the absence of any history of coagulopathy or anticoagulant use. We want to raise public and especially physician awareness that history taking, early diagnosis and managing in right clinical setting play a significant role in survival of these patients.
社区中出现凝血指标升高且伴有无痛性出血的患者,很少会让医生怀疑是超级华法林或杀鼠剂中毒。尽管每年都会诊断出大量超级华法林暴露病例,但我们认为在诊断方面似乎存在延迟,并且在确定治疗和监测这些患者的理想方式时存在困惑。这是对所有已报道的超级华法林中毒病例进行的首次全面文献综述,该综述还研究了临床表现、治疗和随访模式。我们报告一名70岁男性,因鼻出血、黑便、可乐色尿就诊于急诊室,其凝血酶原时间(PT)、活化部分凝血活酶时间(aPTT)和国际标准化比值(INR)升高。混合试验显示凝血障碍完全纠正,提示因子缺乏。进一步询问病史发现,该患者在家中与家庭成员发生争吵,这使我们怀疑其接触了超级华法林。定性溴敌隆检测呈阳性,给予新鲜冰冻血浆和高剂量维生素K1(植物甲萘醌)治疗,并对INR和临床症状进行连续监测。对于出现上述临床和实验室特征的患者,尤其是在没有任何凝血障碍或抗凝药物使用史的情况下,鉴别诊断时应考虑超级华法林中毒。我们希望提高公众尤其是医生的意识,即病史采集、早期诊断以及在正确的临床环境中进行管理,对这些患者的生存起着重要作用。